PDF herunterladen
Semin Hear 2019; 40(02): 108-121
DOI: 10.1055/s-0039-1684041
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

A Review of Cisplatin-Associated Ototoxicity

Jessica Paken
1   Discipline of Audiology, School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa
,
Cyril D. Govender
1   Discipline of Audiology, School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa
,
Mershen Pillay
1   Discipline of Audiology, School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa
,
Vikash Sewram
2   African Cancer Institute
3   Division of Health Systems and Public Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
26. April 2019 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Cisplatin, an effective antineoplastic drug used in the treatment of many cancers, has ototoxic potential, thus placing cancer patients, receiving this treatment, at risk of hearing loss. It is therefore important for health care professionals managing these patients to be aware of cisplatin's ototoxic properties and its clinical signs to identify patients at risk of developing a hearing impairment. Eighty-five English peer-reviewed articles and two books, from January 1975 to July 2015, were identified from PubMed, ScienceDirect, and EBSCOhost. An overview of cisplatin-associated ototoxicity, namely its clinical features, incidence rates, molecular and cellular mechanisms, and risk factors, is presented in this article. This review further highlights the importance of a team-based approach to complement an audiological monitoring program in reducing any further loss in the quality of life of affected patients, as there is currently no otoprotective agent routinely recommended for the prevention of cisplatin-associated ototoxicity.

Keywords

cisplatin - ototoxicity - hearing loss - ototoxicity monitoring program - cancer - otoprotectant

Disclosures

The study is supported by the Medical Research Council of South Africa in terms of the National Health Scholarship Program provided for this purpose by the National Department of Health. The study also received financial support from Oticon Foundation and the University of Kwazulu-Natal. This paper has been presented at the ENT/SAAA/SASLHA Congress 2015 in South Africa, Audiology Australia National Conference 2016, and the World Congress of Audiology 2016.


This paper is a summarized version of Jessica Paken, Cyril D. Govender, Mershen Pillay, and Vikash Sewram, “Cisplatin-Associated Ototoxicity: A Review for the Health Professional,” Journal of Toxicology, Vol. 2016, Article ID 1809394, 13 pages, 2016. https://doi.org/10.1155/2016/1809394.


 

  • References

  • 1 Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65 (02) 87-108
    CrossrefPubMedGoogle Scholar
  • 2 Ferlay J, Soerjomataram I, Dikshit R. , et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11. Lyon, France International Agency for Research on Cancer; 2013
    Google Scholar
  • 3 Rybak LP. Cancer and Ototoxicity of chemotherapeutics. In: Campbell KCM, ed. Pharmacology and Ototoxicity for Audiologists. United States: Thomson Delmar Learning; 2007: 138-162
    Google Scholar
  • 4 Reavis KM, McMillan G, Austin D. , et al. Distortion-product otoacoustic emission test performance for ototoxicity monitoring. Ear Hear 2011; 32 (01) 61-74
    CrossrefPubMedGoogle Scholar
  • 5 Arora R, Thakur JS, Azad RK, Mohindroo NK, Sharma DR, Seam RK. Cisplatin-based chemotherapy: add high-frequency audiometry in the regimen. Indian J Cancer 2009; 46 (04) 311-317
    CrossrefPubMedGoogle Scholar
  • 6 Yorgason JG, Fayad JN, Kalinec F. Understanding drug ototoxicity: molecular insights for prevention and clinical management. Expert Opin Drug Saf 2006; 5 (03) 383-399
    CrossrefPubMedGoogle Scholar
  • 7 Schellack N, Naude A. An overview of pharmacotherapy-induced ototoxicity: review article. S Afr Fam Pract 2013; 55 (04) 357-365
    CrossrefPubMedGoogle Scholar
  • 8 Stearn N, Swanepoel DW. Sensory and neural auditory disorders associated with HIV/AIDS. In: Swanepoel DW, Louw B. , eds. HIV/AIDS Related Communication, Hearing and Swallowing Disorders. San Diego: Plural Publishing; 2010: 243-288
    Google Scholar
  • 9 Gonçalves MS, Silveira AF, Teixeira AR, Hyppolito MA. Mechanisms of cisplatin ototoxicity: theoretical review. J Laryngol Otol 2013; 127 (06) 536-541
    CrossrefPubMedGoogle Scholar
  • 10 Rybak LP. Mechanisms of cisplatin ototoxicity and progress in otoprotection. Curr Opin Otolaryngol Head Neck Surg 2007; 15 (05) 364-369
    CrossrefPubMedGoogle Scholar
  • 11 Olgun Y. Cisplatin ototoxicity: where we are?. J Int Adv Otol 2013; 9 (03) 403-416
    PubMedGoogle Scholar
  • 12 Rybak LP, Husain K, Morris C, Whitworth C, Somani S. Effect of protective agents against cisplatin ototoxicity. Am J Otol 2000; 21 (04) 513-520
    PubMedGoogle Scholar
  • 13 Campbell KC, Kalkanis J, Glatz FR. Ototoxicity: mechanisms, protective agents, and monitoring. Curr Opin Otolaryngol Head Neck Surg 2000; 8 (05) 436-440
    CrossrefPubMedGoogle Scholar
  • 14 Ikeda K, Sunose H, Takasaka T. Effects of free radicals on the intracellular calcium concentration in the isolated outer hair cell of the guinea pig cochlea. Acta Otolaryngol 1993; 113 (02) 137-141
    PubMedGoogle Scholar
  • 15 Mukherjea D, Jajoo S, Whitworth C. , et al. Short interfering RNA against transient receptor potential vanilloid 1 attenuates cisplatin-induced hearing loss in the rat. J Neurosci 2008; 28 (49) 13056-13065
    CrossrefPubMedGoogle Scholar
  • 16 Karasawa T, Steyger PS. An integrated view of cisplatin-induced nephrotoxicity and ototoxicity. Toxicol Lett 2015; 237 (03) 219-227
    CrossrefPubMedGoogle Scholar
  • 17 Schmitt NC, Rubel EW, Nathanson NM. Cisplatin-induced hair cell death requires STAT1 and is attenuated by epigallocatechin gallate. J Neurosci 2009; 29 (12) 3843-3851
    CrossrefPubMedGoogle Scholar
  • 18 Chirtes F, Albu S. Prevention and restoration of hearing loss associated with the use of cisplatin. BioMed Res Int 2014; 2014: 925485
    PubMedGoogle Scholar
  • 19 Callejo A, Sedó-Cabezón L, Juan ID, Llorens J. Cisplatin-induced ototoxicity: effects, mechanisms and protection strategies. Toxics 2015; 3 (03) 268-293
    CrossrefPubMedGoogle Scholar
  • 20 Rybak LP, Ramkumar V. Ototoxicity. Kidney Int 2007; 72 (08) 931-935
    CrossrefPubMedGoogle Scholar
  • 21 Schacht J, Talaska AE, Rybak LP. Cisplatin and aminoglycoside antibiotics: hearing loss and its prevention. Anat Rec (Hoboken) 2012; 295 (11) 1837-1850
    CrossrefPubMedGoogle Scholar
  • 22 Sakamoto M, Kaga K, Kamio T. Extended high-frequency ototoxicity induced by the first administration of cisplatin. Otolaryngol Head Neck Surg 2000; 122 (06) 828-833
    CrossrefPubMedGoogle Scholar
  • 23 Reddel RR, Kefford RF, Grant JM, Coates AS, Fox RM, Tattersall MHN. Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration. Cancer Treat Rep 1982; 66 (01) 19-23
    PubMedGoogle Scholar
  • 24 Moroso MJ, Blair RL. A review of cis-platinum ototoxicity. J Otolaryngol 1983; 12 (06) 365-369
    PubMedGoogle Scholar
  • 25 Schmidt C-M, Knief A, Lagosch AK, Deuster D, am Zehnhoff-Dinnesen A. Left-right asymmetry in hearing loss following cisplatin therapy in children--the left ear is slightly but significantly more affected. Ear Hear 2008; 29 (06) 830-837
    PubMedGoogle Scholar
  • 26 Bokemeyer C, Berger CC, Hartmann JT. , et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer 1998; 77 (08) 1355-1362
    CrossrefPubMedGoogle Scholar
  • 27 Dutta A, Venkatesh MD, Kashyap RC. Study of the effects of chemotherapy on auditory function. Indian J Otolaryngol Head Neck Surg 2005; 57 (03) 226-228
    CrossrefPubMedGoogle Scholar
  • 28 Allen GC, Tiu C, Koike K, Ritchey AK, Kurs-Lasky M, Wax MK. Transient-evoked otoacoustic emissions in children after cisplatin chemotherapy. Otolaryngol Head Neck Surg 1998; 118 (05) 584-588
    PubMedGoogle Scholar
  • 29 Kopelman J, Budnick AS, Sessions RB, Kramer MB, Wong GY. Ototoxicity of high-dose cisplatin by bolus administration in patients with advanced cancers and normal hearing. Laryngoscope 1988; 98 (8, Pt 1): 858-864
    PubMedGoogle Scholar
  • 30 Gratton MA, Salvi RJ, Kamen BA, Saunders SS. Interaction of cisplatin and noise on the peripheral auditory system. Hear Res 1990; 50 (1-2): 211-223
    CrossrefPubMedGoogle Scholar
  • 31 Barr-Hamilton RM, Matheson LM, Keay DG. Ototoxicity of cis-platinum and its relationship to eye colour. J Laryngol Otol 1991; 105 (01) 7-11
    CrossrefPubMedGoogle Scholar
  • 32 Melamed LB, Selim MA, Schuchman D. Cisplatin ototoxicity in gynecologic cancer patients. A preliminary report. Cancer 1985; 55 (01) 41-43
    CrossrefPubMedGoogle Scholar
  • 33 Kirkim G, Olgun Y, Aktas S. , et al. Is there a gender-related susceptibility for cisplatin ototoxicity?. Eur Arch Otorhinolaryngol 2015; 272 (10) 2755-2763
    CrossrefPubMedGoogle Scholar
  • 34 Coradini PP, Cigana L, Selistre SG, Rosito LS, Brunetto AL. Ototoxicity from cisplatin therapy in childhood cancer. J Pediatr Hematol Oncol 2007; 29 (06) 355-360
    CrossrefPubMedGoogle Scholar
  • 35 Helson L, Okonkwo E, Anton L, Cvitkovic E. cis-Platinum ototoxicity. Clin Toxicol 1978; 13 (04) 469-478
    CrossrefPubMedGoogle Scholar
  • 36 Malgonde MS, Nagpure PS, Kumar M. Audiometric patterns in ototoxicity after radiotherapy and chemotherapy in patients of head and neck cancers. Indian J Palliat Care 2015; 21 (02) 164-167
    CrossrefPubMedGoogle Scholar
  • 37 Whitehorn H, Sibanda M, Lacerda M. , et al. High prevalence of cisplatin-induced ototoxicity in Cape Town, South Africa. S Afr Med J 2014; 104 (04) 288-291
    CrossrefPubMedGoogle Scholar
  • 38 Nitz A, Kontopantelis E, Bielack S. , et al. Prospective evaluation of cisplatin- and carboplatin-mediated ototoxicity in paediatric and adult soft tissue and osteosarcoma patients. Oncol Lett 2013; 5 (01) 311-315
    CrossrefPubMedGoogle Scholar
  • 39 Dell'Aringa AHB, Isaac ML, Arruda GV. , et al. Audiological findings in patients treated with radio- and concomitant chemotherapy for head and neck tumors. Radiat Oncol 2009; 4 (01) 53
    CrossrefPubMedGoogle Scholar
  • 40 Schultz C, Goffi-Gomez MVS, Liberman PHP, Carvalho AL. Report on hearing loss in oncology. Rev Bras Otorrinolaringol (Engl Ed) 2009; 75 (05) 634-641
    PubMedGoogle Scholar
  • 41 Zuur CL, Simis YJ, Verkaik RS. , et al. Hearing loss due to concurrent daily low-dose cisplatin chemoradiation for locally advanced head and neck cancer. Radiother Oncol 2008; 89 (01) 38-43
    CrossrefPubMedGoogle Scholar
  • 42 Strumberg D, Brügge S, Korn MW. , et al. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol 2002; 13 (02) 229-236
    CrossrefPubMedGoogle Scholar
  • 43 Nagy JL, Adelstein DJ, Newman CW, Rybicki LA, Rice TW, Lavertu P. Cisplatin ototoxicity: the importance of baseline audiometry. Am J Clin Oncol 1999; 22 (03) 305-308
    CrossrefPubMedGoogle Scholar
  • 44 Waters GS, Ahmad M, Katsarkas A, Stanimir G, McKay J. Ototoxicity due to cis-diamminedichloroplatinum in the treatment of ovarian cancer: influence of dosage and schedule of administration. Ear Hear 1991; 12 (02) 91-102
    CrossrefPubMedGoogle Scholar
  • 45 Knight KR, Kraemer DF, Winter C, Neuwelt EA. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol 2007; 25 (10) 1190-1195
    CrossrefPubMedGoogle Scholar
  • 46 Bertolini P, Lassalle M, Mercier G. , et al. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol 2004; 26 (10) 649-655
    CrossrefPubMedGoogle Scholar
  • 47 Stavroulaki P, Apostolopoulos N, Segas J, Tsakanikos M, Adamopoulos G. Evoked otoacoustic emissions--an approach for monitoring cisplatin induced ototoxicity in children. Int J Pediatr Otorhinolaryngol 2001; 59 (01) 47-57
    CrossrefPubMedGoogle Scholar
  • 48 Tye-Murray N. Foundations of Aural Rehabilitation: Children, Adults, and Their Family Members: Cengage learning: 2014
    PubMed
  • 49 Herbst KG, Humphrey C. Hearing impairment and mental state in the elderly living at home. BMJ 1980; 281 (6245): 903-905
    CrossrefPubMedGoogle Scholar
  • 50 Neuwelt EA, Brock P. Critical need for international consensus on ototoxicity assessment criteria. J Clin Oncol 2010; 28 (10) 1630-1632
    CrossrefPubMedGoogle Scholar
  • 51 Langer T, am Zehnhoff-Dinnesen A, Radtke S, Meitert J, Zolk O. Understanding platinum-induced ototoxicity. Trends Pharmacol Sci 2013; 34 (08) 458-469
    CrossrefPubMedGoogle Scholar
  • 52 Yancey A, Harris MS, Egbelakin A, Gilbert J, Pisoni DB, Renbarger J. Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients. Pediatr Blood Cancer 2012; 59 (01) 144-148
    CrossrefPubMedGoogle Scholar
  • 53 Gurney JG, Tersak JM, Ness KK, Landier W, Matthay KK, Schmidt ML. ; Children's Oncology Group. Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: a report from the Children's Oncology Group. Pediatrics 2007; 120 (05) e1229-e1236
    CrossrefPubMedGoogle Scholar
  • 54 Jacob LCB, Aguiar FP, Tomiasi AA, Tschoeke SN, Bitencourt RF. Auditory monitoring in ototoxicity. Rev Bras Otorrinolaringol (Engl Ed) 2006; 72 (06) 836-844
    CrossrefPubMedGoogle Scholar
  • 55 American Speech Language Hearing Association. Audiologic management of individuals receiving cochleotoxic drug therapy. ASHA 1994; 36 (Suppl. 12) 11-19
    PubMedGoogle Scholar
  • 56 American Academy of Audiology. Position Statement and guidelines: Ototoxicity monitoring. 2009 . Available at: https://audiology-web.s3.amazonaws.com/migrated/OtoMonGuidelines.pdf_539974c40999c1.58842217.pdf . Accessed March 28, 2019
    PubMedGoogle Scholar
  • 57 Dabrowski T, Hussain-Said F. The audiologist's role in ototoxicity monitoring. Advance for Audiologists 2010; 10 (03) 54
    PubMedGoogle Scholar
  • 58 Fausti SA, Wilmington DJ, Helt PV, Helt WJ, Konrad-Martin D. Hearing health and care: the need for improved hearing loss prevention and hearing conservation practices. J Rehabil Res Dev 2005; 42 (04) (Suppl. 02) 45-62
    CrossrefPubMedGoogle Scholar
  • 59 Fausti SA, Helt WJ, Gordon JS. Audiologic monitoring for ototoxicity and patients management. In: Campbell KC. , ed. Pharmacology and Ototoxicity for Audiologists. United States: Thomson Delmar Learning; 2007: 230-251
    Google Scholar
  • 60 Fausti SA, Larson VD, Noffsinger D, Wilson RH, Phillips DS, Fowler CG. High-frequency audiometric monitoring strategies for early detection of ototoxicity. Ear Hear 1994; 15 (03) 232-239
    CrossrefPubMedGoogle Scholar
  • 61 Frank T. High-frequency (8 to 16 kHz) reference thresholds and intrasubject threshold variability relative to ototoxicity criteria using a Sennheiser HDA 200 earphone. Ear Hear 2001; 22 (02) 161-168
    CrossrefPubMedGoogle Scholar
  • 62 Osterhammel D. High frequency audiometry. Clinical aspects. Scand Audiol 1980; 9 (04) 249-256
    CrossrefPubMedGoogle Scholar
  • 63 Campbell KCM. Detection of ototoxicity. Semin Hear 2011; 32 (02) 196-202
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 64 Yu KK, Choi CH, An Y-H. , et al. Comparison of the effectiveness of monitoring Cisplatin-induced ototoxicity with extended high-frequency pure-tone audiometry or distortion-product otoacoustic emission. Korean J Audiol 2014; 18 (02) 58-68
    CrossrefPubMedGoogle Scholar
  • 65 Singh Chauhan R, Saxena RK, Varshey S. The role of ultrahigh-frequency audiometry in the early detection of systemic drug-induced hearing loss. Ear Nose Throat J 2011; 90 (05) 218-222
    CrossrefPubMedGoogle Scholar
  • 66 Rybak LP, Whitworth CA, Mukherjea D, Ramkumar V. Mechanisms of cisplatin-induced ototoxicity and prevention. Hear Res 2007; 226 (1-2): 157-167
    CrossrefPubMedGoogle Scholar
  • 67 Huang MY, Schacht J. Drug-induced ototoxicity. Pathogenesis and prevention. Med Toxicol 1989; 4 (06) 452-467
    CrossrefPubMedGoogle Scholar
  • 68 Rybak LP, Whitworth CA. Ototoxicity: therapeutic opportunities. Drug Discov Today 2005; 10 (19) 1313-1321
    CrossrefPubMedGoogle Scholar
  • 69 Reiter RJ, Tan DX, Korkmaz A, Fuentes-Broto L. Drug-mediated ototoxicity and tinnitus: alleviation with melatonin. J Physiol Pharmacol 2011; 62 (02) 151-157
    PubMedGoogle Scholar
  • 70 Kalkanis JG, Whitworth C, Rybak LP. Vitamin E reduces cisplatin ototoxicity. Laryngoscope 2004; 114 (03) 538-542
    CrossrefPubMedGoogle Scholar
  • 71 Choe WT, Chinosornvatana N, Chang KW. Prevention of cisplatin ototoxicity using transtympanic N-acetylcysteine and lactate. Otol Neurotol 2004; 25 (06) 910-915
    CrossrefPubMedGoogle Scholar
  • 72 Hughes AL, Hussain N, Pafford R, Parham K. Dexamethasone otoprotection in a multidose cisplatin ototoxicity mouse model. Otolaryngol Head Neck Surg 2014; 150 (01) 115-120
    CrossrefPubMedGoogle Scholar
  • 73 Olgun Y, Kırkım G, Kolatan E. , et al. Friend or foe? Effect of oral resveratrol on cisplatin ototoxicity. Laryngoscope 2014; 124 (03) 760-766
    CrossrefPubMedGoogle Scholar
  • 74 Malhotra H. Cisplatin ototoxicity. Indian J Cancer 2009; 46 (04) 262-263
    CrossrefPubMedGoogle Scholar
  • 75 Mukherjea D, Rybak LP. Pharmacogenomics of cisplatin-induced ototoxicity. Pharmacogenomics 2011; 12 (07) 1039-1050
    CrossrefPubMedGoogle Scholar
  • 76 Govender N, Maistry N, Soomar N, Paken J. Hearing loss within a marriage: perceptions of the spouse with normal hearing. S Afr Fam Pract 2014; 56 (01) 50-56
    CrossrefPubMedGoogle Scholar
  • 77 Neumann S, Wolfe J. What's new and notable in hearing aids: a friendly guide for parents and hearing aid wearers. Volta Voices 2013; 20 (03) 24-29
    PubMedGoogle Scholar
  • 78 Parsa V, Scollie S, Glista D, Seelisch A. Nonlinear frequency compression: effects on sound quality ratings of speech and music. Trends Amplif 2013; 17 (01) 54-68
    CrossrefPubMedGoogle Scholar